HematologyNews.net

Hematology Xagena

Xagena Mappa
Medical Meeting
Gastrobase.it
Farmaexplorer.it

Search results for "Idelalisib"

Results from a phase 2 study ( Study 101-08 ) evaluating Idelalisib ( formerly GS-1101 ), an investigational, targeted, oral inhibitor of PI3K delta, in combination with Rituximab ( MabThera, Rituxan ...


Several new, targeted therapies show promise to expand treatment options for chronic lymphocytic leukemia ( CLL ) and are more effective and better tolerated than standard chemotherapy, according to s ...


Patients with relapsed chronic lymphocytic leukemia ( CLL ) who have clinically significant coexisting medical conditions are less able to undergo standard chemotherapy. Effective therapies with accep ...


Phosphatidylinositol-3-kinase delta ( PI3Kδ ) mediates B-cell receptor signaling and microenvironmental support signals that promote the growth and survival of malignant B lymphocytes. In a phase 1 ...